Karo Bio sees future in common cold – acquires Umeå based Tanomed

Karo Bio sees future in common cold – acquires Umeå based Tanomed

The patented technology is based on Swedish research in cooperation with Umeå University and with business development support from Umeå Biotech Incubator. The biology behind the nasal spray relies on combining the enzyme glucose oxidase with glucose, a combination which results in a rise in the local production of hydrogen peroxide in the nose. The elevated levels of hydrogen peroxide effectively counteract rhinovirus infections, as well as other viral and bacterial pathogens. Several clinical studies show that early treatment prevents or reduces disease progression.

This product has great international potential. We expect a market launch to take place within 1-1.5 years, says Anders Lönner, Executive Chairman Karo Bio.

 

Read the press release on
www karobio.se

About Karo Bio
Karo Bio is a development company focused on broadening its operations to include projects and products closer to market. Karo Bio has several projects approaching clinical phase. Karo Bio is based in Huddinge, Sweden and is listed on NASDAQ Stockholm.